When GSK’s new CEO Luke Miels told investors last month that “smart business development” is a key pillar for his strategy, he wasn’t lying. | Like Merck & Co.’s PAH drug Winrevair—which brought in $1 ...

GSK is continuing to bolster its siRNA portfolio by paying $40 million upfront for a pair of oligonucleotide therapies from ...

Eli Casdin, Casdin Capital CEO, joins 'Closing Bell' to discuss the biotech sector, the stocks Casdin favors and much more.

Industry leaders met in San Diego to debate whether U.S. biotechs are losing ground to China. Meanwhile, across the Pacific, ...

Building an AI infrastructure for biotech. Bacteria that munch on cancer. How to best make a cold brew. All that and more in ...

Come to the Biotech Career & Futures Fair, where representatives of top biotech and biopharmaceutical companies will discuss their current and future job openings. The event is open to all Wake Tech ...

As Demy-Colton and EBD Group’s Biotech Showcase™ concluded its 18th year SAN FRANCISCO, CA, UNITED STATES, February 10, ...

Raleigh-based Slate Medicines just pulled in a hefty $130 million Series A, a war chest the startup says will fuel development of SLTE‑1009, an in‑licensed anti‑PACAP monoclonal antibody aimed at ...

O]ur companies have until June of 2028 to get there. That should not be a sigh of relief. That should be a, oh my gosh, we've ...

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.